Restricted accessResearch articleFirst published online 2013-12
Radionuclide Therapy of Painful Bone Metastases—A Comparative Study Between Consecutive Radionuclide Infusions,Combination With Chemotherapy,and Radionuclide Infusions Alone
Radionuclides have been long used for the palliation of skeletal-related metastatic pain. They are almost invariably used as the last resource for pain palliation. Their use as single agents with dose escalations, in combination with biphosphonates or chemotherapy is well known in the peer-reviewed literature; however, little is known about the combination between different agents. In our study, we used consecutive administration of 2 different radionuclides such as 186Re-1,1-hydroxyethylidenediphosphonate (186Re-HEDP) and 89Strontium Chloride (89Sr-Cl) separated by adequate period of time to allow bone marrow recovery in patients with high chance of bone pain relapse and compared it with 89Sr-Cl and chemotherapy group and 186Re-HEDP with bisphosphonates. The end result was that treatment with consecutive radionuclides was much more effective and safe than the other 2 groups.
ErnstDSTannockIFWinquistEW. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol. 2003;21(17):3335–3342.
2.
SaadFGleasonDMMurrayR. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458–1468.
3.
SteenlandELeerJWvan HouwelingenH. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol. 1999;52(2):101–109.
4.
ArcangeliGGiovinazzoGSaracinoB. Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration. Int J Radiat Oncol Biol Phys. 1998;42(5):1119–1126.
5.
LewingtonVJ. Targeted radionuclide therapy for bone metastases. Eur J Nucl Med. 1993;20(1):66–74.
6.
DebesJDTindallDJ. The role of androgens and the androgen receptor in prostate cancer. Cancer Lett. 2002;187(1-2):1–7.
7.
GilliganTKantoffPW. Chemotherapy for prostate cancer. Urology., 2002;60(3 suppl 1):94–100.
8.
NielsenOSMunroAJTannockIF. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991;9(3):509–524.
9.
SerafiniAN. Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease. Int J Radiat Oncol Biol Phys. 1994;30(5):1187–1194.
10.
LiepeKRungeRKotzerkeJ. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J Cancer Res Clin Oncol. 2005;131(1):60–66.
11.
LiepeKRungeRKotzerkeJ. Systemic radionuclide therapy in pain palliation. Am J Hosp Palliat Care. 2005;22(6):457–464.
12.
CiprianiCAtzeiGArgiròG. Gamma camera imaging of osseous metastatic lesions by strontium-89 bremsstrahlung. Eur J Nucl Med. 1997;24(11):1356–1361.
13.
UchiyamaMNaritaHMakinoM. Strontium-89 therapy and imaging with bremsstrahlung in bone metastases. Clin Nucl Med. 1997;22(9):605–609.
14.
MaxonHR 3rdSchroderLEHertzbergVS. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med. 1991;32(10):1877–1881.
15.
FinlayIGMasonMDShelleyM. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005;6(6):392–400.
16.
LewingtonVJ.Bone-seeking radionuclides for therapy. J Nucl Med. 2005;46(suppl 1):38S–47S.
17.
ScottJHuskissonEC. Graphic representation of pain. Pain. 1976;2(2):175–84.
18.
MorVLaliberteLMorrisJNWiemannM.The karnofsky performance status scale. An examination of its reliability and validity in a research setting. Cancer. 1984;53(9):2002–2007.
19.
Cancer pain relief and palliative care. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1990;804:1–75.
20.
PayneR. Chronic pain: challenges in the assessment and management of cancer pain. J Pain Symptom Manage. 2000;19(suppl 1):S12–S15.
21.
SwarmRAbernethyAPAnghelescuDL. Adult cancer pain. J Natl Compr Canc Netw. 2010;8(9):1046–1086.
22.
AuclercGAntoineECCajfingerFBrunet-PommeyrolAAgaziaCKhayatD. Management of advanced prostate cancer. Oncologist. 2000;5(1):36–44.
23.
KudachadkarRO'ReganRM. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. CA Cancer J Clin. 2005;55(3):145–163.
24.
TannockIFde WitRBerryWR. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512.
25.
BerensonJRVescioRHenickK. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer, 2001;91(1):144–154.
26.
SaadF. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid. Semin Oncol. 2002;29(6 suppl 21):19–27.
27.
SaartoTJanesRTenhunenMKouriM. Palliative radiotherapy in the treatment of skeletal metastases. Eur J Pain. 2002;6(5):323–330.
28.
PatchellRATibbsPARegineWF. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366(9486):643–648.
29.
Cancer pain relief and palliative care. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser1990;804:1–75.
30.
FischerMKampenWU. Radionuclide therapy of bone metastases. Breast Care (Basel). 2012;7(2):100–107.
31.
BishayeeARaoDVSrivastavaSCBouchetLGBolchWEHowellRW. Marrow-sparing effects of 117mSn(4+)diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer. J Nucl Med. 2000;41(12):2043–2050.
32.
de KlerkJMvan het SchipADZonnenbergBA. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations. J Nucl Med. 1994;35(9):1423–1428.
33.
DafermouAColamussiPGigantiMCittantiCBestagnoMPiffanelliA. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med. 2001;28(7):788–798.
34.
SciutoRFestaATofaniA. Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy. Clin Ter. 1998;149(921):43–47.
35.
TuSMMillikanREMengistuB. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357(9253):336–341.
36.
AmatoRJHernandez-McClainJHenaryH. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer. Am J Clin Oncol. 2008;31(6):532–538.
37.
ZafeirakisAZissimopoulosABaziotisNLimourisGS. Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice. Cancer Biother Radiopharm. 2009;24(5):543–550.
38.
LimourisGSShuklaSKCondi-PaphitiA. Palliative therapy using rhenium-186-HEDP in painful breast osseous metastases. Anticancer Res. 1997;17(3B):1767–1772.
39.
SciutoRFestaAPasqualoniR. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat. 2001;66(2):101–109.
40.
TomblynM. The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases. Cancer Control. 2012;19(2):137–144.
